Hyper-fractionation and hypo-fractionation are two approaches to delivering radiation therapy that differ from the conventional fractionation schedule. These approaches can indeed influence resistance patterns in tumors, although the effects can vary depending on the specific context, including the type of cancer, the biological characteristics of the tumor, and the overall treatment plan.

1. **Hyper-fractionation** involves delivering smaller doses of radiation per session but increasing the number of sessions. This approach aims to exploit the differential repair capabilities between normal and cancerous tissues, potentially reducing late side effects and allowing for a higher total dose to be delivered. By increasing the total dose, hyper-fractionation can potentially overcome resistance in some tumors, especially those with rapid repopulation rates.

2. **Hypo-fractionation** involves delivering larger doses of radiation per session over fewer sessions. This approach can be more convenient for patients and may enhance the biological effectiveness of the treatment due to the higher dose per fraction. Hypo-fractionation can be particularly effective in tumors with low alpha/beta ratios, such as prostate cancer, where it may overcome resistance by delivering a more potent dose per session.

Both hyper- and hypo-fractionation can alter the tumor microenvironment and influence the mechanisms of resistance. For example, they can affect the repair of sublethal damage, reoxygenation, repopulation, and redistribution of cancer cells within the cell cycle. These changes can either enhance or reduce the effectiveness of radiation therapy, depending on the specific tumor biology.

Ultimately, the choice between hyper-fractionation, hypo-fractionation, and conventional fractionation should be based on a thorough understanding of the tumor's characteristics, patient-specific factors, and the goals of treatment. Clinical trials and ongoing research continue to refine these approaches to optimize outcomes and manage resistance in various cancer types.